X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11192) 11192
Book Review (1532) 1532
Publication (951) 951
Newsletter (188) 188
Book Chapter (19) 19
Conference Proceeding (19) 19
Magazine Article (16) 16
Dissertation (5) 5
Book / eBook (2) 2
Newspaper Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9976) 9976
humans (8573) 8573
interferon-alpha - pharmacology (4006) 4006
male (3268) 3268
animals (3162) 3162
female (3142) 3142
interferon-alpha (2890) 2890
pharmacology & pharmacy (2409) 2409
adult (2201) 2201
middle aged (2196) 2196
interferon-alpha - therapeutic use (2190) 2190
recombinant proteins (2112) 2112
interferon (1888) 1888
immunology (1796) 1796
mice (1795) 1795
oncology (1697) 1697
antiviral agents - pharmacology (1433) 1433
antiviral agents - therapeutic use (1379) 1379
aged (1295) 1295
interferon-alpha - administration & dosage (1183) 1183
treatment outcome (1139) 1139
cells, cultured (1114) 1114
expression (1040) 1040
hepatitis c, chronic - drug therapy (1040) 1040
therapy (1031) 1031
biological response modifiers (966) 966
biochemistry & molecular biology (958) 958
cell line (946) 946
drug therapy, combination (944) 944
interferon alpha (938) 938
virology (931) 931
hepatitis c (832) 832
ribavirin - therapeutic use (830) 830
abridged index medicus (796) 796
cell biology (774) 774
cancer (770) 770
health aspects (761) 761
tumor cells, cultured (748) 748
infection (723) 723
cell line, tumor (701) 701
hepacivirus - drug effects (692) 692
interferon-alpha - adverse effects (692) 692
medicine, research & experimental (683) 683
interferon-gamma - pharmacology (681) 681
activation (677) 677
ribavirin (677) 677
dose-response relationship, drug (669) 669
gastroenterology & hepatology (647) 647
antineoplastic agents - pharmacology (646) 646
cytokines (643) 643
hepatitis c virus (643) 643
interferon-alpha - metabolism (634) 634
time factors (628) 628
polyethylene glycols - therapeutic use (598) 598
hepacivirus - genetics (595) 595
research (578) 578
infectious diseases (556) 556
cells (553) 553
signal transduction (553) 553
antineoplastic agents - therapeutic use (550) 550
hematology (550) 550
virus replication - drug effects (530) 530
apoptosis (522) 522
care and treatment (519) 519
analysis (509) 509
hepatitis c - drug therapy (504) 504
virus-infection (490) 490
dendritic cells (480) 480
immunotherapy (479) 479
antiviral agents - administration & dosage (477) 477
proteins (474) 474
phosphorylation (473) 473
gene-expression (470) 470
drug therapy (462) 462
genotype (461) 461
interferon-alpha - immunology (457) 457
gene expression (456) 456
in-vitro (453) 453
molecular sequence data (449) 449
carcinoma, renal cell - drug therapy (448) 448
antineoplastic combined chemotherapy protocols - therapeutic use (444) 444
kidney neoplasms - drug therapy (444) 444
hepatitis (439) 439
rats (437) 437
viruses (432) 432
virus diseases (431) 431
recombinant proteins - pharmacology (430) 430
induction (428) 428
interferon-beta - pharmacology (428) 428
cell division - drug effects (426) 426
mice, inbred c57bl (423) 423
apoptosis - drug effects (420) 420
signal transduction - drug effects (419) 419
drug synergism (412) 412
ribavirin - pharmacology (408) 408
adolescent (405) 405
ifn-alpha (405) 405
chronic hepatitis-c (402) 402
interferon-alpha - biosynthesis (399) 399
article (394) 394
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10823) 10823
Chinese (247) 247
Russian (120) 120
Japanese (62) 62
French (51) 51
Spanish (34) 34
German (23) 23
Polish (20) 20
Italian (7) 7
Hungarian (6) 6
Dutch (5) 5
Turkish (4) 4
Ukrainian (3) 3
Hebrew (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2013, Volume 71, Issue 5, pp. 1297 - 1307
To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K... 
Resistance | Angiogenesis | Medicine & Public Health | VEGFr tyrosine kinase inhibitor | Kidney cancer | mTOR inhibitor | Oncology | Cancer Research | Pharmacology/Toxicology | MAMMALIAN TARGET | RAPAMYCIN | EVEROLIMUS | GUIDELINES | NVP-BEZ235 | CANCER | TRIAL | INTERFERON-ALPHA | ONCOLOGY | TEMSIROLIMUS | mTOR inhibitor Resistance | PHARMACOLOGY & PHARMACY | PHASE-I | Niacinamide - analogs & derivatives | Humans | Imidazoles - administration & dosage | Drug Resistance, Neoplasm | Antineoplastic Agents - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - administration & dosage | Quinolines - pharmacology | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Sunitinib | Carcinoma, Hepatocellular - drug therapy | Indoles - pharmacology | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Aminopyridines - administration & dosage | Sirolimus - analogs & derivatives | Carcinoma, Renal Cell - pathology | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Liver Neoplasms - drug therapy | Morpholines - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Imidazoles - pharmacology | Pyrimidines - pharmacology | Sirolimus - pharmacology | Sirolimus - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrroles - pharmacology | Signal Transduction - drug effects | Aminopyridines - pharmacology | Sorafenib | Carcinoma, Hepatocellular - pathology | Cell Line, Tumor | Kidney Neoplasms - pathology | Cell Proliferation - drug effects | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Kidney Neoplasms - drug therapy | Antimitotic agents | Benchmarks | Carcinoma, Renal cell | Antineoplastic agents | Vascular endothelial growth factor | Analysis | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2013, Volume 57, Issue 3, pp. 1312 - 1322
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2012, Volume 56, Issue 11, pp. 5728 - 5734
Journal Article
Antiviral Research, ISSN 0166-3542, 02/2016, Volume 126, pp. 69 - 80
Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are... 
Antiviral agents | Innate immunity | Virus-host interaction | Immune responses | Influenza A virus | HUMAN MACROPHAGES | INFLUENZA-A-VIRUS | VIRAL-INFECTIONS | NS1 PROTEIN | RNA-BINDING | ANTIVIRAL RESPONSES | NEURAMINIDASE INHIBITORS | VIROLOGY | EPITHELIAL-CELLS | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | PYRIMIDINE BIOSYNTHESIS | Interferon-alpha - drug effects | Coinfection - drug therapy | Humans | Deoxycytidine - pharmacology | Phosphoproteins - metabolism | Salicylates - pharmacology | Macrophages - virology | Influenza, Human - virology | Antineoplastic Agents - pharmacology | Influenza, Human - drug therapy | Macrophages - immunology | Amides - pharmacology | Influenza A virus - physiology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Cytokines - metabolism | Immunity, Innate - drug effects | RNA, Viral - biosynthesis | Cells, Cultured | Coinfection - virology | Interferon-alpha - immunology | Pyrroles - pharmacology | Lipopolysaccharides - pharmacology | Macrophages - drug effects | Oxazoles - pharmacology | Thiazoles - pharmacology | Influenza A virus - drug effects | Virus Replication - physiology | Deoxycytidine - analogs & derivatives | Immunologic Factors - pharmacology | Influenza, Human - immunology | Epidemics | Analysis | Influenza | Interferon alpha | Global economy | Biological response modifiers | Health aspects | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2014, Volume 58, Issue 2, pp. 647 - 653
Journal Article
PLoS Pathogens, ISSN 1553-7366, 07/2012, Volume 8, Issue 7, pp. 22 - e1002832
Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure, and... 
WILD-TYPE | RAPID VIRAL RESPONSE | ENZYMATIC-ACTIVITIES | PRECLINICAL PROFILE | MICROBIOLOGY | HCV INFECTION | INTERFERON-ALPHA | VIROLOGY | IN-VIVO | GENOTYPE 1 INFECTION | ANTIVIRAL EFFICACY | SERINE-PROTEASE | PARASITOLOGY | Hepatitis C - drug therapy | Proline - metabolism | Humans | Hepacivirus - genetics | Structure-Activity Relationship | Antiviral Agents - metabolism | Protease Inhibitors - pharmacology | Indoles - metabolism | Viral Nonstructural Proteins - chemistry | Antiviral Agents - chemistry | Lactams - pharmacology | Proline - pharmacology | Indoles - pharmacology | Protease Inhibitors - therapeutic use | Oligopeptides - chemistry | Hepacivirus - drug effects | Protein Structure, Tertiary | Antiviral Agents - pharmacology | Proline - analogs & derivatives | Sulfonamides - chemistry | Models, Molecular | Protease Inhibitors - chemistry | Protease Inhibitors - metabolism | Oligopeptides - metabolism | Sulfonamides - pharmacology | Lactams - metabolism | Proline - chemistry | Drug Resistance, Viral - genetics | Hepatitis C - virology | Sulfonamides - metabolism | Oligopeptides - pharmacology | Viral Nonstructural Proteins - antagonists & inhibitors | Indoles - chemistry | Lactams - chemistry | Virus diseases | Viral drug resistance | Research | Protease inhibitors | Properties | Observations | Hepatitis | Liver cancer | Liver diseases | Ligands | Genetic diversity | Drug resistance | Pharmaceutical industry | Cancer therapies | Viral infections | Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 3, pp. 538 - 543
Background & Aims Chronic hepatitis C virus (HCV) infection is characterised by a failure of virus-specific CD8+ T cells that is mainly caused by viral escape... 
Gastroenterology and Hepatology | T cell exhaustion | Antiviral therapy | Immune response | Hepatitis C virus | T cell restoration | DAA | CD127 EXPRESSION | PHENOTYPE | CD8(+) T-CELLS | RESPONSES | INHIBITION | HEPATITIS-C VIRUS | CD4(+) | INFECTION | VIRAL PERSISTENCE | GASTROENTEROLOGY & HEPATOLOGY | PD-1 | Acrylates - therapeutic use | Hepatitis C, Chronic - pathology | CD8-Positive T-Lymphocytes - pathology | Humans | Middle Aged | Male | Recombinant Proteins | Thiazoles - therapeutic use | Contraindications | Oligopeptides - therapeutic use | Acrylates - pharmacology | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Virus Replication - drug effects | Antiviral Agents - pharmacology | Polyethylene Glycols | Antiviral Agents - therapeutic use | Interferon-alpha | Ribavirin - therapeutic use | Cell Proliferation - physiology | Cells, Cultured | Treatment Outcome | Hepatitis C, Chronic - drug therapy | CD8-Positive T-Lymphocytes - physiology | CD8-Positive T-Lymphocytes - drug effects | Benzimidazoles - pharmacology | Aged | Cell Proliferation - drug effects | Thiazoles - pharmacology | In Vitro Techniques | Oligopeptides - pharmacology | Virus Replication - physiology | Ribavirin - pharmacology | Interferon | Biological response modifiers | T cells | Hepatitis C | Health aspects | Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 62, Issue 5, pp. 1008 - 1014
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2010, Volume 54, Issue 5, pp. 1878 - 1887
Journal Article
Blood, ISSN 0006-4971, 04/2001, Volume 97, Issue 7, pp. 1999 - 2007
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, pp. e71057 - e71057
Therapeutic oligonucleotides including siRNA and immunostimulatory ligands of Toll-like receptors (TLR) or RIG-I like helicases (RLH) are a promising novel... 
PLASMACYTOID DENDRITIC CELLS | ACTIVATION | RNA | RECOGNITION | MULTIDISCIPLINARY SCIENCES | INNATE IMMUNE-RESPONSE | NORMAL VOLUNTEERS | RIG-I | INDUCTION | CPG OLIGONUCLEOTIDES | IFN-ALPHA | Toll-Like Receptor 7 - agonists | DEAD Box Protein 58 | Interferon-alpha - metabolism | Leukocytes, Mononuclear - drug effects | Leukocytes, Mononuclear - secretion | Humans | RNA, Small Interfering - pharmacology | Cells, Cultured | Imidazoles - pharmacology | Transfection | Anticoagulants - pharmacology | Leukocytes, Mononuclear - immunology | Edetic Acid - pharmacology | Lipopolysaccharides - pharmacology | Toll-Like Receptor 4 - agonists | DEAD-box RNA Helicases - metabolism | Drug Evaluation, Preclinical | Oligodeoxyribonucleotides - pharmacology | Heparin - pharmacology | Cytokines - blood | Heparin | Vaccines | Cytokines | Health aspects | Immunotherapy | Drugs | Intravenous administration | Oligonucleotides | Drug development | Assaying | Blood | Immunosuppressive agents | Hirudin | Gene sequencing | Lipopolysaccharides | Proteins | Ethics | Receptors | Ethylenediaminetetraacetic acids | DNA methylation | Toll-like receptors | Peripheral blood mononuclear cells | Drug dosages | Deoxyribonucleic acid--DNA | CpG islands | Immune system | Heparan sulfate | Anticoagulants | Immune response | TLR7 protein | Immunostimulation | Blood & organ donations | Adjuvants | siRNA | Pharmacology | Pattern recognition | TLR4 protein | RNA polymerase | TLR9 protein | Immune systems | Side effects | Hospitals | Ribonucleic acids | Ligands | In vivo methods and tests | Interferon | Human behavior | In vitro methods and tests | Cancer | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article